Welcome to our dedicated page for Theravance Bioph SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA interactions for YUPELRI or the latest ampreloxetine trial update often means digging through hundreds of pages. Theravance Biopharma SEC filings are dense with clinical data, royalty math, and milestone clauses—details investors cannot afford to miss.
Our platform turns that complexity into clarity. Stock Titan’s AI delivers plain-English summaries of every Theravance Biopharma annual report 10-K, flags changes in risk factors between quarters, and highlights where collaboration revenue shows up in the Theravance Biopharma quarterly earnings report 10-Q filing.
Need to know when executives act on conviction? Receive Theravance Biopharma Form 4 insider transactions in real-time and spot buying or selling ahead of pivotal readouts. Material events like FDA meeting outcomes are surfaced through Theravance Biopharma 8-K material events explained so you can react quickly.
- AI-powered context for “Theravance Biopharma proxy statement executive compensation”
- Side-by-side trend charts for revenue from YUPELRI across filings
- Keyword search to locate trial discontinuations or safety signals instantly
Whether you are asking, “How do I read Theravance Biopharma’s 10-K?” or “Where can I see Theravance Biopharma insider trading Form 4 transactions?” the answers are here—updated the moment a document hits EDGAR. Save hours and make decisions faster by understanding Theravance Biopharma SEC documents with AI instead of wading through technical language yourself.
From Theravance Biopharma executive stock transactions Form 4 to a Theravance Biopharma earnings report filing analysis, every disclosure is explained simply, giving you the clarity you need to track organ-selective innovation with confidence.
Theravance Biopharma (NASDAQ: TBPH) filed an 8-K disclosing that China’s NMPA approved YUPELRI (revefenacin), the first once-daily nebulized LAMA for COPD in China.
The decision triggers a $7.5 million one-time milestone payment from partner Viatris, expected in Q3 2025, and entitles Theravance to additional sales-based milestones and tiered royalties on Chinese net sales. Viatris will fund and manage all development and commercialization activities.
No other financial statements were furnished; the disclosure is limited to Item 8.01 and Exhibit 99.1.
Rick E. Winningham, CEO and Director of Theravance Biopharma, reported a significant insider transaction on June 23, 2025. The executive made a bona fide gift of 20,000 ordinary shares with no compensation received.
Following the transaction, Winningham's holdings include:
- 1,733,180 shares held directly
- 13,500 shares held as custodian
- 92,567 shares held in trust
The Form 4 filing indicates Winningham maintains substantial ownership in the company despite the gifted shares. The transaction was executed under regular conditions and was not part of a Rule 10b5-1 trading plan. The filing was completed through his attorney-in-fact, Brett A. Grimaud, on June 25, 2025.
FAQ
What is the current stock price of Theravance Bioph (TBPH)?
What is the market cap of Theravance Bioph (TBPH)?
What is Theravance Biopharma's core business?
What key products does the company offer?
How does Theravance Biopharma generate revenue?
What distinguishes its research and development strategy?
How does the company maintain its industry credibility?
What are the potential challenges it faces?
